Diligence memo · auto-generated · as of July 1, 2026
IMMUTEP Ltd
IMMUTEP Ltd looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
IMMUTEP Ltd operates in Biotechnology, based in Sydney, NSW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
IMMUTEP Ltd has raised $11M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.2M on 2018-12-20.
Most recent recorded round closed around 2019-07-17.
Valuation (modeled)modeled
Provath models IMMUTEP Ltd at approximately $19M (range $568K–$102M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.10× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 10.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 58% of Biotechnology peers (4291 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., Arrakis Therapeutics, Inc., TechAccel, LLC, Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.